{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:31:16Z","timestamp":1787160676278,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,6]]},"DOI":"10.7759\/cureus.66280","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T10:59:42Z","timestamp":1722941982000},"source":"Crossref","is-referenced-by-count":7,"title":["The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight\/Obese Adolescents Without Diabetes Mellitus: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Nilesh T","family":"Katole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh V","family":"Salankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay M","family":"Khade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti S","family":"Kale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandkishor J","family":"Bankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punam","family":"Gosavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhushan","family":"Dudhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishikant","family":"Mankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obaid","family":"Noman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Obesity Atlas 2023. (2023). Accessed. June 20, 2024: https:\/\/www.worldobesity.org\/resources\/resource-library\/world-obesity-atlas-2023."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12334","article-title":"Predicting adult obesity from childhood obesity: a systematic review and meta-analysis","volume":"17","author":"Simmonds M","year":"2016","unstructured":"Simmonds M, Llewellyn A, Owen CG, Woolacott N. Predicting adult obesity from childhood obesity: a systematic review and meta-analysis. Obes Rev. 2016, 17:95-107. 10.1111\/obr.12334","journal-title":"Obes Rev"},{"key":"ref3","article-title":"Fighting obesity in children from European World Health Organization member states. Epidemiological data, medical-social aspects, and prevention programs","volume":"170","author":"Nittari G","year":"2019","unstructured":"Nittari G, Scuri S, Petrelli F, Pirillo I, di Luca NM, Grappasonni I. Fighting obesity in children from European World Health Organization member states. Epidemiological data, medical-social aspects, and prevention programs. Clin Ter. 2019, 170:e223-30.","journal-title":"Clin Ter"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32129-3","article-title":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128\u00b79 million children, adolescents, and adults","volume":"390","year":"2017","unstructured":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016. a pooled analysis of 2416 population-based measurement studies in 128\u00b79 million children, adolescents, and adults. Lancet. 2017, 390:2627-42. 10.1016\/S0140-6736(17)32129-3","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.obmed.2024.100545","article-title":"Efficacy of liraglutide in pediatric obesity: a review of clinical trial data","volume":"48","author":"Agosta M","year":"2024","unstructured":"Agosta M, Sofia M, Pezzino S, et al.. Efficacy of liraglutide in pediatric obesity: a review of clinical trial data. Obes Med. 2024, 48:100545. 10.1016\/j.obmed.2024.100545","journal-title":"Obes Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2012.144","article-title":"Pharmacotherapy for childhood obesity: present and future prospects","volume":"37","author":"Sherafat-Kazemzadeh R","year":"2013","unstructured":"Sherafat-Kazemzadeh R, Yanovski SZ, Yanovski JA. Pharmacotherapy for childhood obesity: present and future prospects. Int J Obes (Lond). 2013, 37:1-15. 10.1038\/ijo.2012.144","journal-title":"Int J Obes (Lond)"},{"key":"ref7","unstructured":"Novo Nordisk. FDA approves once-weekly Wegovy injection for the treatment of obesity in teens aged 12 years and older. (2022). Accessed: June 20, 2024: https:\/\/www.novonordisk-us.com\/media\/news-archive\/news-details.html?id=151389."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck MA","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021, 46:101102. 10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01179-1","article-title":"Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis","volume":"19","author":"Dagenais GR","year":"2020","unstructured":"Dagenais GR, Ryd\u00e9n L, Leiter LA, et al.. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovasc Diabetol. 2020, 19:199. 10.1186\/s12933-020-01179-1","journal-title":"Cardiovasc Diabetol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen SL","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019, 7:776-85. 10.1016\/S2213-8587(19)30249-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13177","article-title":"GLP-1 agonists for obesity and type 2 diabetes in children: systematic review and meta-analysis","volume":"22","author":"Chadda KR","year":"2021","unstructured":"Chadda KR, Cheng TS, Ong KK. GLP-1 agonists for obesity and type 2 diabetes in children: systematic review and meta-analysis. Obes Rev. 2021, 22:e13177. 10.1111\/obr.13177","journal-title":"Obes Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2021.05.009","article-title":"Safety and efficacy of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity: a meta-analysis","volume":"236","author":"Ryan PM","year":"2021","unstructured":"Ryan PM, Seltzer S, Hayward NE, Rodriguez DA, Sless RT, Hawkes CP. Safety and efficacy of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity: a meta-analysis. J Pediatr. 2021, 236:137-47.e13. 10.1016\/j.jpeds.2021.05.009","journal-title":"J Pediatr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/children10020208","article-title":"Efficacy of liraglutide in obesity in children and adolescents: systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Cornejo-Estrada A","year":"2023","unstructured":"Cornejo-Estrada A, Nieto-Rodr\u00edguez C, Le\u00f3n-Figueroa DA, Moreno-Ramos E, Cabanillas-Ramirez C, Barboza JJ. Efficacy of liraglutide in obesity in children and adolescents: systematic review and meta-analysis of randomized controlled trials. Children (Basel). 2023, 10:208. 10.3390\/children10020208","journal-title":"Children (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.337","article-title":"Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study","volume":"20","author":"Kelly AS","year":"2012","unstructured":"Kelly AS, Metzig AM, Rudser KD, et al.. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity (Silver Spring). 2012, 20:364-70. 10.1038\/oby.2011.337","journal-title":"Obesity (Silver Spring)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2013.1045","article-title":"The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial","volume":"167","author":"Kelly AS","year":"2013","unstructured":"Kelly AS, Rudser KD, Nathan BM, et al.. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr. 2013, 167:355-60. 10.1001\/jamapediatrics.2013.1045","journal-title":"JAMA Pediatr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12624","article-title":"A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity","volume":"15","author":"Weghuber D","year":"2020","unstructured":"Weghuber D, Forslund A, Ahlstr\u00f6m H, et al.. A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity. Pediatr Obes. 2020, 15:e12624. 10.1111\/ijpo.12624","journal-title":"Pediatr Obes"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2016.10.076","article-title":"Liraglutide in an adolescent population with obesity: a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of liraglutide in adolescents aged 12-17 years","volume":"181","author":"Danne T","year":"2017","unstructured":"Danne T, Biester T, Kapitzke K, et al.. Liraglutide in an adolescent population with obesity: a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of liraglutide in adolescents aged 12-17 years. J Pediatr. 2017, 181:146-53.e3. 10.1016\/j.jpeds.2016.10.076","journal-title":"J Pediatr"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12495","article-title":"Liraglutide effects in a paediatric (7-11\u00a0y) population with obesity: a randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics","volume":"14","author":"Mastrandrea LD","year":"2019","unstructured":"Mastrandrea LD, Witten L, Carlsson Petri KC, Hale PM, Hedman HK, Riesenberg RA. Liraglutide effects in a paediatric (7-11\u00a0y) population with obesity: a randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. Pediatr Obes. 2019, 14:e12495. 10.1111\/ijpo.12495","journal-title":"Pediatr Obes"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly AS","year":"2020","unstructured":"Kelly AS, Auerbach P, Barrientos-Perez M, et al.. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020, 382:2117-28. 10.1056\/NEJMoa1916038","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber D","year":"2022","unstructured":"Weghuber D, Barrett T, Barrientos-P\u00e9rez M, et al.. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022, 387:2245-57. 10.1056\/NEJMoa2208601","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/s0889-8529(03)00071-9","article-title":"Obesity and type 2 diabetes","volume":"32","author":"Maggio CA","year":"2003","unstructured":"Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am. 2003, 32:805-22. 10.1016\/s0889-8529(03)00071-9","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060640","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity","volume":"151","author":"Hampl SE","year":"2023","unstructured":"Hampl SE, Hassink SG, Skinner AC, et al.. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023, 151:10.1542\/peds.2022-060640","journal-title":"Pediatrics"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78371","article-title":"Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight","volume":"124","author":"Baggio LL","year":"2014","unstructured":"Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014, 124:4223-6. 10.1172\/JCI78371","journal-title":"J Clin Invest"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1055\/a-1844-1176","article-title":"The antiobesity effect and safety of GLP-1 receptor agonist in overweight\/obese patients without diabetes: a systematic review and meta-analysis","volume":"54","author":"Guo X","year":"2022","unstructured":"Guo X, Zhou Z, Lyu X, et al.. The antiobesity effect and safety of GLP-1 receptor agonist in overweight\/obese patients without diabetes: a systematic review and meta-analysis. Horm Metab Res. 2022, 54:458-71. 10.1055\/a-1844-1176","journal-title":"Horm Metab Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.obmed.2022.100456","article-title":"Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: systematic review and meta-analysis","volume":"35","author":"Vosoughi K","year":"2022","unstructured":"Vosoughi K, Roghani RS, Camilleri M. Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: systematic review and meta-analysis. Obes Med. 2022, 35:100456. 10.1016\/j.obmed.2022.100456","journal-title":"Obes Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau J","year":"2015","unstructured":"Lau J, Bloch P, Sch\u00e4ffer L, et al.. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015, 58:7370-80. 10.1021\/acs.jmedchem.5b00726","journal-title":"J Med Chem"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell J","year":"2017","unstructured":"Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017, 19:1242-51. 10.1111\/dom.12932","journal-title":"Diabetes Obes Metab"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12839","article-title":"Semaglutide as a promising antiobesity drug","volume":"20","author":"Christou GA","year":"2019","unstructured":"Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obes Rev. 2019, 20:805-15. 10.1111\/obr.12839","journal-title":"Obes Rev"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu L","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022, 13:1043789. 10.3389\/fendo.2022.1043789","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi M","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023, 330:1795-7. 10.1001\/jama.2023.19574","journal-title":"JAMA"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/269077-the-antiobesity-effect-and-safety-of-glp-1-receptor-agonist-in-overweightobese-adolescents-without-diabetes-mellitus-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T10:59:49Z","timestamp":1722941989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/269077-the-antiobesity-effect-and-safety-of-glp-1-receptor-agonist-in-overweightobese-adolescents-without-diabetes-mellitus-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.66280","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,6]]}}}